Anthony R. Mato, MD, MSCE

Articles by Anthony R. Mato, MD, MSCE

Closing Remarks on Upcoming Data and Future Perspectives in MCL and CLL

ByAnthony R. Mato, MD, MSCE,Catherine C. Coombs, MD,Alexey V. Danilov, MD, PhD,Matthew S. Davids, MD, MMSc,Michael Wang, MD

September 15th 2022

Looking to the future, a panel of experts offers closing remarks on research in CLL and MCL including hopes for further data on bispecific antibodies, BTK degraders, CAR T-cell therapy, and pirtobrutinib.

Pirtobrutinib and Other Non-Covalent BTK Inhibitors in the Treatment of CLL

ByAnthony R. Mato, MD, MSCE,Catherine C. Coombs, MD,Alexey V. Danilov, MD, PhD,Matthew S. Davids, MD, MMSc,Michael Wang, MD

September 15th 2022

The assembled faculty comment on data on the role of non-covalent BTK inhibitors in the CLL treatment landscape, with emphasis on the phase 1/2 BRUIN trial of pirtobrutinib.

Anti-CD20 Regimens and Triplet Therapies in CLL

ByAnthony R. Mato, MD, MSCE,Catherine C. Coombs, MD,Alexey V. Danilov, MD, PhD,Matthew S. Davids, MD, MMSc,Michael Wang, MD

September 9th 2022

Orienting the conversation around anti-CD20-drug-based combination and sequencing approaches, the panelists examine key takeaways from the CLL13 and CLL14 clinical trials as well as expectations for real-world data in the future.

Considerations for COVID-19 in MCL and CLL

ByAnthony R. Mato, MD, MSCE,Catherine C. Coombs, MD,Alexey V. Danilov, MD, PhD,Matthew S. Davids, MD, MMSc,Michael Wang, MD

September 9th 2022

Focusing the discussion on the current state of the COVID-19 pandemic, Catherine C. Coombs, MD, shares key insights into the use of COVID-19 pre-exposure prevention for patients with CLL or MCL.

The Potential Role of Venetoclax Combination Approaches in CLL

ByAnthony R. Mato, MD, MSCE,Catherine C. Coombs, MD,Alexey V. Danilov, MD, PhD,Matthew S. Davids, MD, MMSc,Michael Wang, MD

September 2nd 2022

Experts in hematologic malignancies reflect on clinical trials studying venetoclax combination approaches including the CAPTIVATE, FLAIR, GLOW, VISION, SEQUOIA, and MAJIC studies.

TRANSCEND CLL: CAR T-cell Therapy for CLL

ByAnthony R. Mato, MD, MSCE,Catherine C. Coombs, MD,Alexey V. Danilov, MD, PhD,Matthew S. Davids, MD, MMSc,Michael Wang, MD

September 2nd 2022

Panelists respond to a question from Michael Wang, MD, about the role of CAR T-cell therapy in CLL, and Brian T. Hill, MD, PhD, summarizes takeaways from the TRANSCEND CLL study.

Emerging Approaches in CLL

ByAnthony R. Mato, MD, MSCE,Catherine C. Coombs, MD,Alexey V. Danilov, MD, PhD,Matthew S. Davids, MD, MMSc,Michael Wang, MD

August 26th 2022

The faculty members share expert insights into treatment approaches for patients with double-refractory chronic lymphocytic leukemia.

Updates from Patient-reported QOL and Matching-adjusted Indirect Treatment Comparisons (MAICs) Studies in CLL

ByAnthony R. Mato, MD, MSCE,Catherine C. Coombs, MD,Alexey V. Danilov, MD, PhD,Matthew S. Davids, MD, MMSc,Michael Wang, MD

August 26th 2022

Brian T. Hill, MD, PhD, and Matthew S. Davids, MD, MMSc, address the role of study design in CLL to highlight the importance of patient-reported QOL outcomes and matching-adjusted indirect treatment comparisons (MAICs).

Dr. Mato on Factors for Choosing BTK Inhibitors or Venetoclax in CLL

ByAnthony R. Mato, MD, MSCE

August 22nd 2022

Anthony Mato, MD, MSCE, discusses the factors used to make treatment decisions between BTK inhibitors and venetoclax in chronic lymphocytic leukemia.

Treatment Decision-making Among Second-generation BTKis in CLL

ByAnthony R. Mato, MD, MSCE,Catherine C. Coombs, MD,Alexey V. Danilov, MD, PhD,Matthew S. Davids, MD, MMSc,Michael Wang, MD

August 19th 2022

Key opinion leaders in CLL review factors driving therapeutic decision-making among the available second-generation BTK inhibitors including efficacy and safety considerations.

Zanubrutinib in CLL: The ALPINE Trial

ByAnthony R. Mato, MD, MSCE,Catherine C. Coombs, MD,Alexey V. Danilov, MD, PhD,Matthew S. Davids, MD, MMSc,Michael Wang, MD

August 19th 2022

An expert in hematologic malignancies, Catherine C. Coombs, MD, shares insights gleaned from the ALPINE clinical trial of zanubrutinib vs ibrutinib for relapsed/refractory CLL.

Acalabrutinib in CLL: Insights from the ELEVATE TN and ASCEND Trials

ByAnthony R. Mato, MD, MSCE,Catherine C. Coombs, MD,Alexey V. Danilov, MD, PhD,Matthew S. Davids, MD, MMSc,Michael Wang, MD

August 12th 2022

Highlighting the ELEVATE TN and ASCEND clinical trials, panelists share expert insights into the next-generation BTK inhibitor acalabrutinib for CLL.

Treatment Overview: Chronic Lymphocytic Leukemia

ByAnthony R. Mato, MD, MSCE,Catherine C. Coombs, MD,Alexey V. Danilov, MD, PhD,Matthew S. Davids, MD, MMSc,Michael Wang, MD

August 12th 2022

Catherine C. Coombs, MD, leads the faculty in a discussion of the current treatment landscape for CLL with a review of considerations for patients with high-risk or relapsed/refractory disease.

Advancements on the Horizon in Mantle Cell Lymphoma

ByAnthony R. Mato, MD, MSCE,Catherine C. Coombs, MD,Alexey V. Danilov, MD, PhD,Matthew S. Davids, MD, MMSc,Michael Wang, MD

August 5th 2022

Thought leaders in hematologic malignancies reflect on studies of ROR1 and share perspectives on advancements on the horizon for mantle cell lymphoma.

Strategies for Sequencing and Combining Therapies in MCL

ByAnthony R. Mato, MD, MSCE,Catherine C. Coombs, MD,Alexey V. Danilov, MD, PhD,Matthew S. Davids, MD, MMSc,Michael Wang, MD

August 5th 2022

A panel of distinguished faculty builds a lively conversation on the emergence of pirtobrutinib and its effect on treatment sequencing strategies in MCL as well as the overall role of doublet and triplet regimens.

CAR T-Cell Therapy in R/R MCL

ByAnthony R. Mato, MD, MSCE,Catherine C. Coombs, MD,Alexey V. Danilov, MD, PhD,Matthew S. Davids, MD, MMSc,Michael Wang, MD

July 29th 2022

Michael Wang, MD, guides the panel in a discussion on CAR T-cell therapy for relapsed/refractory MCL including a summary of key takeaways from the ZUMA-2 trial and a conversation on real-world vs clinical trial data.

BTK Inhibitors in Relapsed/Refractory MCL and Treatment Selection

ByAnthony R. Mato, MD, MSCE,Catherine C. Coombs, MD,Alexey V. Danilov, MD, PhD,Matthew S. Davids, MD, MMSc,Michael Wang, MD

July 29th 2022

Panelists discuss treatment considerations in the use of BTK inhibitors for relapsed/refractory mantle cell lymphoma, with Matthew S. Davids, MD, MMSc, reviewing strategies for the management of AEs.

Second-line Therapies in MCL: Regimens With BTK Inhibitors and BCL-2 Targeting Therapies

ByAnthony R. Mato, MD, MSCE,Catherine C. Coombs, MD,Alexey V. Danilov, MD, PhD,Matthew S. Davids, MD, MMSc,Michael Wang, MD

July 22nd 2022

Key opinion leaders in mantle cell lymphoma discuss the emergence of more effective novel therapies such as BTK inhibitors and BCL-2 inhibitors and whether there is a continued role for lenalidomide-based regimens.

Mantle Cell Lymphoma Maintenance Strategies

ByAnthony R. Mato, MD, MSCE,Catherine C. Coombs, MD,Alexey V. Danilov, MD, PhD,Matthew S. Davids, MD, MMSc,Michael Wang, MD

July 22nd 2022

A panel of experts in hematologic malignancies discusses maintenance strategies for mantle cell lymphoma with particular emphasis on treatment considerations related to the COVID-19 pandemic and real-world data.

Factors for Consideration in Treatment Decision-making for MCL

ByAnthony R. Mato, MD, MSCE,Catherine C. Coombs, MD,Alexey V. Danilov, MD, PhD,Matthew S. Davids, MD, MMSc,Michael Wang, MD

July 15th 2022

Focusing on the differences in treatment considerations between younger and older patients, Michael Wang, MD, discusses the current treatment landscape in mantle cell lymphoma.

Disease Overview: Mantle Cell Lymphoma

ByAnthony R. Mato, MD, MSCE,Catherine C. Coombs, MD,Alexey V. Danilov, MD, PhD,Matthew S. Davids, MD, MMSc,Michael Wang, MD

July 15th 2022

Anthony R. Mato, MD, MSCE, introduces the panel, and Alexey V. Danilov, MD, PhD, provides an overview of the incidence, presentation, pathologic features, and treatment landscape for mantle cell lymphoma.

Optimizing the Treatment of CLL With Novel Therapies

ByWilliam G. Wierda, MD, PhD,Jacqueline C. Barrientos, MD, MS,Catherine C. Coombs, MD,Nicole Lamanna, MD,Anthony R. Mato, MD, MSCE,Deborah M. Stephens, DO

March 14th 2022

Oncologist-hematologists discuss the outlook for treating patients with chronic lymphocytic leukemia with newer novel therapies.

CAR T-Cell Therapies in CLL

ByWilliam G. Wierda, MD, PhD,Jacqueline C. Barrientos, MD, MS,Catherine C. Coombs, MD,Nicole Lamanna, MD,Anthony R. Mato, MD, MSCE,Deborah M. Stephens, DO

March 14th 2022

Take-home messages from ASH 2021 regarding the role of CAR T-cell therapies in chronic lymphocytic leukemia.

PI3K Inhibitors for CLL

ByWilliam G. Wierda, MD, PhD,Jacqueline Barrientos, MD, MS,Catherine C. Coombs, MD,Nicole Lamanna, MD,Anthony R. Mato, MD, MSCE,Deborah M. Stephens, DO

March 7th 2022

A comparison of 3 PI3K inhibitors—idelalisib, duvelisib, and umbralisib—as treatment for chronic lymphocytic leukemia.

Novel Therapies for CLL: Sequencing Strategies

ByWilliam G. Wierda, MD, PhD,Anthony R. Mato, MD, MSCE,Nicole Lamanna, MD,Catherine C. Coombs, MD

February 28th 2022

Factors that impact decisions for frontline and subsequent lines of therapy for patients with chronic lymphocytic leukemia.

Chemotherapy-Free Regimens as Frontline Therapy in CLL

ByWilliam G. Wierda, MD, PhD,Nicole Lamanna, MD,Catherine C. Coombs, MD,Anthony R. Mato, MD, MSCE,Jacqueline Barrientos, MD, MS

February 21st 2022

Key takeaways of the CLL13 (GAIA) clinical trial based on highlights presented at ASH 2021.

Fixed-Duration Therapy in Relapsed/Refractory CLL: Ibrutinib Plus Venetoclax

ByWilliam G. Wierda, MD, PhD,Jacqueline Barrientos, MD, MS,Nicole Lamanna, MD,Anthony R. Mato, MD, MSCE

February 14th 2022

Considerations for treating patients with relapsed/refractory chronic lymphocytic leukemia with the combination of ibrutinib and venetoclax.

Fixed-Duration Therapy in Frontline CLL: Venetoclax Plus Obinutuzumab

ByWilliam G. Wierda, MD, PhD,Anthony R. Mato, MD, MSCE,Catherine C. Coombs, MD,Deborah M. Stephens, DO

February 14th 2022

The rationale for investigating the fixed-duration, all-oral combination regimen of venetoclax with obinutuzumab as treatment for chronic lymphocytic leukemia.

Fixed-Duration Therapy in Frontline CLL: Ibrutinib Plus Venetoclax

ByWilliam G. Wierda, MD, PhD,Anthony R. Mato, MD, MSCE,Catherine C. Coombs, MD

February 7th 2022

Key takeaways from the CAPTIVATE and GLOW trials of ibrutinib plus venetoclax as fixed-duration frontline therapy for chronic lymphocytic leukemia.

Frontline Therapy for CLL: Treatment Selection Based on Patient and Treatment Factors

ByWilliam G. Wierda, MD, PhD,Jacqueline Barrientos, MD, MS,Anthony R. Mato, MD, MSCE,Deborah M. Stephens, DO

February 7th 2022

Variables that impact which Bruton tyrosine kinase inhibitor is most appropriate as frontline therapy for patients with newly diagnosed chronic lymphocytic leukemia and the role of patient and disease factors in treatment selection.